Can targeted radiation boost Immunotherapy's power against head and neck cancer?

NCT ID NCT03283605

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This trial is testing whether adding targeted radiation (SBRT) to two immunotherapy drugs, durvalumab and tremelimumab, can better control metastatic head and neck cancer. The study includes adults with this cancer that has spread, and the radiation is given between cycles of the drugs. The goal is to see if this combination is safe and whether it can slow cancer progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
durvalumab, tremelimumab, and stereotactic body radiotherapy (SBRT)
What this could lead to
If successful, this combination could offer a new way to control metastatic head and neck cancer, potentially extending the time before the disease progresses.
What could go wrong
This is an early-phase trial with a small number of participants, so the benefits are uncertain. The combination may cause severe side effects, and it is not yet known if it will improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Centre Hospitalier de l'Université de Montréal

    Montreal, Quebec, H2L 4M1, Canada

  • Cross Cancer Institute

    Edmonton, Alberta, T6G 1Z2, Canada

  • London Regional Cancer Program of the Lawson Health Research Institute

    London, Ontario, N6A 4L6, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.